A current update on ADHD pharmacogenomics

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Goldman L, Genel M, Bezman R, Slanetz P: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA279(14),1100–1107 (1998).
  Medline CASGoogle Scholar
• 2  Kieling C, Goncalves R, Tannock R, Castellanos F: Neurobiology of attention deficit hyperactivity disorder. Child. Adolesc. Psychiatr. Clin. N. Am.17(2),285–307, viii (2008).
  MedlineGoogle Scholar
• 3  Stein M, McGough J: The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child. Adolesc. Psychiatr. Clin. N. Am.17(2),475–490, xi–xii (2008).
  MedlineGoogle Scholar
• 4  Polanczyk G, Zeni C, Genro J, Roman T, Hutz M, Rohde L: Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics6(3),225–234 (2005).
  CASGoogle Scholar
• 5  Vandenbergh D, Persico A, Hawkins A et al.: Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics14(4),1104–1106 (1992).
  Medline CASGoogle Scholar
• 6  Gizer I, Ficks C, Waldman I: Candidate gene studies of ADHD: a meta-analytic review. Hum. Genet.126(1),51–90 (2009).
  Medline CASGoogle Scholar
• 7  Winsberg B, Comings D: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child. Adolesc. Psychiatry38(12),1474–1477 (1999).
  Medline CASGoogle Scholar
• 8  Roman T, Szobot C, Martins S, Biederman J, Rohde L, Hutz M: Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics12(6),497–499 (2002).
  Medline CASGoogle Scholar
• 9  Kirley A, Lowe N, Hawi Z et al.: Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. B. Neuropsychiatr. Genet.121B(1),50–54 (2003).
  Google Scholar
• 10  Stein M, Waldman I, Sarampote C et al.: Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology30(7),1374–1382 (2005).
  Medline CASGoogle Scholar
• 11  van der Meulen E, Bakker S, Pauls D et al.: High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J. Child. Psychol. Psychiatry46(10),1074–1080 (2005).
  MedlineGoogle Scholar
• 12  Langley K, Turic D, Peirce T et al.: No support for association between the dopamine transporter (DAT1) gene and ADHD. Am. J. Med. Genet. B. Neuropsychiatr. Genet.139B(1),7–10 (2005).
  Medline CASGoogle Scholar
• 13  McGough J, McCracken J, Swanson J et al.: Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry45(11),1314–1322 (2006).
  MedlineGoogle Scholar
• 14  Zeni C, Guimarães A, Polanczyk G et al.: No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet.144B(3),391–394 (2007).
  MedlineGoogle Scholar
• 15  Joober R, Grizenko N, Sengupta S et al.: Dopamine transporter 3´-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology32(6),1370–1376 (2007).
  Medline CASGoogle Scholar
• 16  Tharoor H, Lobos E, Todd R, Reiersen A: Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(4),527–530 (2008).
  MedlineGoogle Scholar
• 17  Kereszturi E, Tarnok Z, Bognar E et al.: Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(8),1431–1435 (2008).
  Medline CASGoogle Scholar
• 18  Purper-Ouakil D, Wohl M, Orejarena S et al.: Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(8),1425–1430 (2008).▪▪ Presents a meta-analysis of 475 subjects from previous reports, suggesting a significant association between the 10/10 genotype and methylphenidate (MPH) response.
  Medline CASGoogle Scholar
• 19  Gruber R, Joober R, Grizenko N, Leventhal B, Cook EJ, Stein M: Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol.19(3),233–239 (2009).
  MedlineGoogle Scholar
• 20  Leddy J, Waxmonsky J, Salis R et al.: Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J. Child. Adolesc. Psychopharmacol.19(2),127–136 (2009).
  MedlineGoogle Scholar
• 21  McGough J, McCracken J, Loo S et al.: A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry (2009) (Epub ahead of print).
  Google Scholar
• 22  Mick E, Biederman J, Spencer T, Faraone S, Sklar P: Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am. J. Med. Genet. B. Neuropsychiatr. Genet.141B(8),890–894 (2006).
  Medline CASGoogle Scholar
• 23  Kooij J, Boonstra A, Vermeulen S et al.: Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(2),201–208 (2008).
  MedlineGoogle Scholar
• 24  Rohde L, Roman T, Szobot C, Cunha R, Hutz M, Biederman J: Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse48(2),87–89 (2003).
  Medline CASGoogle Scholar
• 25  Cheon K, Ryu Y, Kim J, Cho D: The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur. Neuropsychopharmacol.15(1),95–101 (2005).
  Medline CASGoogle Scholar
• 26  Loo S, Specter E, Smolen A, Hopfer C, Teale P, Reite M: Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J. Am. Acad. Child. Adolesc. Psychiatry42(8),986–993 (2003).
  MedlineGoogle Scholar
• 27  Bellgrove M, Hawi Z, Kirley A, Fitzgerald M, Gill M, Robertson I: Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology30(12),2290–2297 (2005).
  Medline CASGoogle Scholar
• 28  Gilbert D, Wang Z, Sallee F et al.: Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain129(Pt 8),2038–2046 (2006).
  MedlineGoogle Scholar
• 29  Oldenhof J, Vickery R, Anafi M et al.: SH3 binding domains in the dopamine D4 receptor. Biochemistry37(45),15726–15736 (1998).
  Medline CASGoogle Scholar
• 30  Gelernter J, Kennedy J, van Tol H, Civelli O, Kidd K: The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. Genomics13(1),208–210 (1992).
  Medline CASGoogle Scholar
• 31  Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson P: Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol. Psychiatry5(4),396–404 (2000).
  Medline CASGoogle Scholar
• 32  Seeger G, Schloss P, Schmidt M: Marker gene polymorphisms in hyperkinetic disorder – predictors of clinical response to treatment with methylphenidate? Neurosci. Lett.313(1–2),45–48 (2001).
  Medline CASGoogle Scholar
• 33  Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J: Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J. Child. Adolesc. Psychopharmacol.14(4),564–574 (2004).
  MedlineGoogle Scholar
• 34  Cheon K, Kim B, Cho S: Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology32(6),1377–1383 (2007).
  Medline CASGoogle Scholar
• 35  Hoehe M, Otterud B, Hsieh W et al.: Genetic mapping of adrenergic receptor genes in humans. J. Mol. Med.73(6),299–306 (1995).
  Medline CASGoogle Scholar
• 36  Polanczyk G, Zeni C, Genro J et al.: Association of the adrenergic a2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry64(2),218–224 (2007).▪ Presents the first evidence of a role for the ADRA2A gene on the effect of MPH on attentive symptoms of attention deficit–hyperactivity disorder.
  Medline CASGoogle Scholar
• 37  da Silva T, Pianca T, Roman T et al.: Adrenergic α2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. J. Neural. Transm.115(2),341–345 (2008).
  Medline CASGoogle Scholar
• 38  Cheon K, Cho D, Koo M, Song D, Namkoong K: Association between homozygosity of a G allele of the α-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biol. Psychiatry65(7),564–570 (2009).
  Medline CASGoogle Scholar
• 39  Arnsten A: Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs23(Suppl. 1),33–41 (2009).
  Medline CASGoogle Scholar
• 40  Stevenson J, Langley K, Pay H et al.: Attention deficit hyperactivity disorder with reading disabilities: preliminary genetic findings on the involvement of the ADRA2A gene. J. Child. Psychol. Psychiatry46(10),1081–1088 (2005).
  Medline CASGoogle Scholar
• 41  Keulers E, Hendriksen J, Feron F et al.: Methylphenidate improves reading performance in children with attention deficit hyperactivity disorder and comorbid dyslexia: an unblinded clinical trial. Eur. J. Paediatr. Neurol.11(1),21–28 (2007).
  MedlineGoogle Scholar
• 42  Lotta T, Vidgren J, Tilgmann C et al.: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry34(13),4202–4210 (1995).
  Medline CASGoogle Scholar
• 43  Cheon K, Jun J, Cho D: Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. Int. Clin. Psychopharmacol.23(5),291–298 (2008).
  MedlineGoogle Scholar
• 44  Sengupta S, Grizenko N, Schmitz N et al.: COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD. Neuropsychopharmacology33(13),3069–3077 (2008).
  Medline CASGoogle Scholar
• 45  Mick E, Neale B, Middleton F, McGough J, Faraone S: Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(8),1412–1418 (2008).
  Medline CASGoogle Scholar
• 46  Yang L, Wang Y, Li J, Faraone S: Association of norepinephrine transporter gene with methylphenidate response. J. Am. Acad. Child. Adolesc. Psychiatry43(9),1154–1158 (2004).
  MedlineGoogle Scholar
• 47  Manor I, Laiba E, Eisenberg J et al.: Association between tryptophan hydroxylase 2, performance on a continuance performance test and response to methylphenidate in ADHD participants. Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(8),1501–1508 (2008).
  Medline CASGoogle Scholar
• 48  Sinzig J, Döpfner M, Lehmkuhl G et al.: Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol.17(4),421–432 (2007).
  MedlineGoogle Scholar
• 49  Guimarães A, Zeni C, Polanczyk G et al.: MAOA is associated with methylphenidate improvement of oppositional symptoms in boys with attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol.12(5),709–714 (2009).
  Medline CASGoogle Scholar
• 50  Zhu H, Patrick K, Yuan H et al.: Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet.82(6),1241–1248 (2008).
  Medline CASGoogle Scholar
• 51  Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M: Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology57(7–8),731–733 (2009).▪ Evaluates the association of MPH response with a gene related to its pharmacokinetics.
  Medline CASGoogle Scholar
• 52  Michelson D, Faries D, Wernicke J et al.: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose–response study. Pediatrics108(5),E83 (2001).
  Medline CASGoogle Scholar
• 53  Michelson D, Read H, Ruff D, Witcher J, Zhang S, McCracken J: CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry46(2),242–251 (2007).
  MedlineGoogle Scholar
• 54  Trzepacz P, Williams D, Feldman P, Wrishko R, Witcher J, Buitelaar J: CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur. Neuropsychopharmacol.18(2),79–86 (2008).
  Medline CASGoogle Scholar
• 55  Ramoz N, Boni C, Downing A et al.: A haplotype of the norepinephrine transporter (Net) gene SLC6A2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology34(9),2135–2142 (2009).
  Medline CASGoogle Scholar
• 56  Altman D: Better reporting of randomised controlled trials: the CONSORT statement. BMJ313(7057),570–571 (1996).
  Medline CASGoogle Scholar
• 57  Everitt B, Wessely S: Clinical Trials in Psychiatry. John Wiley & Sons, NJ, USA (2008).
  Google Scholar
• 58  Polanczyk G, Faraone S, Bau C et al.: The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am. J. Med. Genet. B. Neuropsychiatr. Genet.147B(8),1419–1424 (2008).▪▪ Meta-regression analysis that demonstrates the feasibility of multisite pharmacogenetic studies across different continents.
  Medline CASGoogle Scholar
• 59  Kieling C, Rohde L: Challenges and opportunities in ADHD pharmacogenomics. Pharmacogenomics9(9),1193–1194 (2008).
  Google Scholar